Join to View Full Profile
1 N Waukegan RdDept R435, Bldg Ap30-3North Chicago, IL 60064
Phone+1 847-935-1293
Fax+1 847-938-3711
Dr. Brun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolResidency, Ophthalmology, 1994 - 1997
MedStar Franklin Square Medical CenterResidency, Internal Medicine, 1993 - 1994
Johns Hopkins University School of MedicineClass of 1993
Certifications & Licensure
IL State Medical License 1997 - 2017
Clinical Trials
- Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients Start of enrollment: 2000 Jul 01
- Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects Start of enrollment: 2002 Jul 01
Publications & Presentations
PubMed
- 95 citationsA 96-Week Comparison of Lopinavir- Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination TherapyD. William Cameron, Barbara A. da Silva, Jose R. Arribas, Robert A. Myers, Nicholaos C. Bellos
The Journal of Infectious Diseases. 2008-07-15 - 528 citationsLow-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapySarah Palmer, Frank Maldarelli, Ann Wiegand, Barry Bernstein, George J. Hanna
Proceedings of the National Academy of Sciences of the United States of America. 2008-03-11 - 48 citationsSeven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick
HIV Clinical Trials. 2008-01-01
Press Mentions
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. To Board of DirectorsJune 28th, 2021
Horizon Therapeutics Plc Announces TEPEZZA® (Teprotumumab-Trbw) Selected as a Winner of the R&D 100 AwardOctober 5th, 2020- Axial Biotherapeutics Strengthens and Expands Board of Directors and Leadership TeamFebruary 12th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
